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A novel combined treatment of conventional chemotherapy
with an intratumoral injection of syngeneic dendritic cells
(DCs) has emerged as a potent cancer treatment strategy. In
this study, we evaluated the synergistic effect of an intraperi-
toneal (i.p.) injection of a chemotherapeutic drug, paclitaxel,
and an intratumoral (i.t.) injection of syngeneic bone marrow-
derived DCs for the treatment of pre-existing fibrosarcoma.
Subcutaneous tumors were established using MCA102 fibro-
sarcoma cells in syngeneic C57BL/6 mice. The results de-
monstrated that the combined treatment of paclitaxel che-
motherapy and the injection of DCs led to complete tumor
regression, in contrast to only partial eradication of the
tumors with chemotherapy or DCs alone. Furthermore, the
tumor-free mice were able to resist a repeat challenge with
the same type of tumor. These findings suggest that a
combination therapy of systemic chemotherapy along with
the intratumoral administration of DCs is a potent treatment
strategy for fibrosarcoma.
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INTRODUCTION
Dendritic cells (DCs) are the most effective
antigen-presenting cells recognized by T cells, and
they have the potential to induce tumor-specific
immune responses leading to tumor rejection.
DCs capture tumor cells, then generate tumor-
specific cytotoxic T lymphocytes (CTLs) from
naive T cells to fight against tumor cells.
1-3 Al-
though tumors have immunogenic epitopes on
their surface that can be recognized by the host
immune system, failure to produce an appropriate
immune response to these antigens results in
uncontrolled tumor growth in cancer patients.
Immune tolerance to an established tumor is due
to the low immunogenicity of the tumor and/or
defects in the host immune system.
4-6
Several published trials investigating the
immune system's ability to overcome tumor toler-
ance involve the development of a tumor vaccina-
tion that injects DCs, generated and loaded with
tumor antigens ex vivo into cancer patients.
7-11
Using these approaches, ex vivo manipulation of
the DCs is required for the cells to acquire and
present tumor-specific antigens. To avoid the re-
quirement of an ex vivo antigen loading process,
some researchers have suggested the administra-
tion of a DC injection after systemic chemo-
therapy; this strategy is based on the ability of
DCs to ingest apoptotic tumor cells and acquire
tumor-associated antigens, which induces class
I-restricted CTLs in vitro.
12-15 These trials showed
that the antitumor effect was significantly more
effective when both chemotherapy and an injec-
tion of DCs were administered.
Paclitaxel is an anticancer drug that is effective
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against a variety of cancers. Paclitaxel binds to
tubulin, retards microtubule depolymerization,
impairs mitosis, blocks cell cycle progression, and
facilitates apoptosis.
16 Various chemotherapeutic
drugs are currently being used for combination
therapy studies of DCs and chemotherapy.
Paclitaxel was tested for use as a treatment for
advanced stage breast cancer in an animal mo-
del.
15 Recently, it was reported that the cytotoxic
effect of paclitaxel on DCs was minimal.
17 In our
study, we observed an antitumor effect associated
with a DC therapy after low-dose paclitaxel admi-
nistration for the treatment of murine fibrosar-
coma. The results indicate that the intratumoral
(i.t.) administration of DCs after low-dose chemo-
therapy via an intraperitoneal (i.p.) injection
results in potent and specific antitumor immunity,




MCA102 is a murine fibrosarcoma cell line of
C57BL/6 mouse origin. This cell line was main-
tained in a complete medium that contained RPMI
1640 medium (Gibco-BRL, Rockville, MD, USA)
plus 10% heat-inactivated fetal bovine serum (FBS,
Gibco-BRL) and 100 U/mL penicillin (GIBCO-
BRL) in a 5% CO2 incubator at 37 to a subcon-
fluent state in 75 cm
2 plates. After reaching sub-
confluency, cells were rinsed twice with phosphate-
buffered saline (PBS) or RPMI 1640. For detach-
ment, cells grown to confluency were treated with
0.05% trypsin (Gibco-BRL) and 0.53 mM EDTA.
For the in vivo inoculation, tumor cells were
washed three times and resuspended in PBS.
Murine DC culture
Primary DCs were obtained from mouse bone
marrow precursors. Murine bone marrow cells
were harvested from femurs and tibias and then
plated in complete RPMI1640 containing recombi-
nant murine GM-CSF (10 ng/mL) and recombi-
nant murine IL-4 (10 ng/mL). On day two, non-
adherent granulocytes were gently removed, and
fresh medium with GM-CSF and IL-4 was added.
On day four, loosely adherent cells were dis-
lodged and replated. On day six of the culture,
immature DCs and non-adherent proliferating
aggregates were collected and the maturation
status and percentage of DCs were verified by
flow cytometry with five surface markers (CD11c,
CD44, CD40, CD80, and MHC class antigen
I-Ad), showing the purity of DCs to be >65%.
MTT assay
The number of viable cells at the end of the
culture was quantified by an MTT assay. The
tumor cells and DCs in their own complete media
were incubated for 48 hr in 24-well plates con-
taining serial dilutions of the chemotherapeutic
drugs in a total volume of 1 mL/well. The concen-
trations of the dilutions of etoposide, doxorubicin
and ifosfamide used were: 0.005, 0.01, 0.05, 0.1, 0.5
and 1 ug/mL. The concentrations of the dilutions
of paclitaxel used: were 0.005, 0.01, 0.05 0.1, 1, 5,
10 and 50 ug/mL. MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (Sigma),
was dissolved in PBS at 5 mg/mL. Following
exposure to the chemotherapeutic drugs, a 1 : 10
diluted MTT solution (0.5 mg/mL) was added to
the assay wells. The plates were incubated at 37
for 24 hr. Viable cells generated insoluble crystals,
but DCs were floating and loosely attached on the
surface of the culture plates. Therefore, 200
uL/well 10% SDS solution containing 0.01 N HCl
was directly added into the wells to avoid the
potential loss of cells and to dissolve the insoluble
crystal generated by the cells. After 24 hr, the
amount of converted MTT was quantified in an
ELISA reader using a 570 nm test and 650 nm
reference wavelengths. The results are expressed
as the mean ± SD of absorbance.
Animals
Female C57BL/6 mice were purchased from
Dae Han Bio Link (Korea). The mice were allowed
to adjust to their environment for one week, and
DC isolation was performed at six to eight weeks
of age, and tumor inoculation was performed at
eight to ten weeks of age.Combined Chemotherapy and Dendritic Cells for Treatment of Murine Fibrosarcoma
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Combined treatment of intratumoral DC injection
and chemotherapy
For the fibrosarcoma MCA102 tumor model,
naive C57BL/6 mice were inoculated s.c with 1.5
×10
5 MCA102 cells in the upper right flank. On
day nine, when the tumor size reached 3-5 mm
in diameter, paclitaxel (5 mg/kg) was admini-
stered i.p. to the mice and then the same treat-
ment was given on the 11th and 13th days. DCs
were injected i.t. once daily four times, on days
10, 12, 14 and 18 (2×10
6 cells/mouse for each
injection in 50 ul of PBS). Mice were divided into
four groups (four mice per group): untreated
control mice, mice treated with DCs alone, mice
treated with paclitaxel alone, and mice treated
with paclitaxel plus DCs. For all animal experi-
ments, the tumor size was measured biweekly
using a caliper and expressed as the product of
the maximal perpendicular diameter and height
(mm
3).
In vivo analysis of cell death by TUNEL stain
The free 3-OH strand breaks resulting from
DNA degradation were detected by the terminal
deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) technique. After a wash
with PBS, tissue slides were fixed in 10% para-
formaldehyde. The TUNEL assay was conducted
according to the manufacturer's instructions
(TACS In Situ Apoptosis Detection kit, Trevision,
USA).
Secondary tumor challenge in tumor-free mice
The persistence of tumor-specific immunity in
the mice treated by combination therapy was
determined at day 74, 146 days after first tumor
inoculation. Two mice showing a complete re-
gression of MCA102 fibrosarcoma tumors were
given a second s.c. tumor challenge. MCA102
fibrosarcoma tumor cells (2×10
5 cell each in 50 uL
PBS) were implanted into the left upper flank of
each mouse, opposite to the first injection site. The
same number of tumor cells was also injected into
age-matched control mice. These mice were fol-
lowed for survival and measurement of tumor
size.
RESULTS
Isolation of bone marrow-derived dendritic cells
and phenotyping
Primary DCs were obtained from syngeneic
mouse bone marrow precursors from femurs and
tibias. On day six of the culture, in the presence
of GM-CSF and IL-4, immature DCs were col-
lected and their phenotypes were verified by flow
cytometry (Fig. 1). As shown in Fig. 1, almost no
expression of maturity surface markers CD40 and
CD80 was detected, indicating that the DCs were
in an immature state. Flow cytometry data with
three other surface markers, I-Ad, CD11c, and
CD44, showed the purity of the DCs to be >65%.
Fig. 1. Phenotyping of cultured
dendritic cells. Primary DCs
were obtained from syngeneic
mouse bone marrow precursors
by culturing in the presence of
GM-CSF and IL-4; their pheno-
types were verified by flow
cytometry. The results showed
that the DCs isolated were
CD11c (B), CD44 (C), and I-Ad
(D) positive. Both CD40 (E) and
CD80 (F) expression was very
low.Gwang-Seong Choi, et al.
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In vitro cytotoxic effect of paclitaxel on murine
fibrosarcoma cells and DCs
In order to find an effective chemotherapeutic
agent for MCA102 tumor cells, the cytotoxicity of
etoposide, ifosfamide, doxorubicine, and pacli-
taxel were tested by the MTT assay in vitro.
Among these, paclitaxel had the most significant
cytotoxic effect on MCA102 tumor cells (Fig. 2A).
In addition, the cytotoxic effect of paclitaxel on
DCs was also tested and shown to have a lower
cytotoxic effect than that on MCA102 (Fig. 2B).
These results suggested that paclitaxel would be
an effective chemotherapeutic agent for this
study.
Significant regression of tumor growth in the
combined treatment group in contrast to control
single treatment groups
To determine whether systemic paclitaxel admi-
nistration by i.p. together with an i.t. injection of
DCs has a synergistic effect compared to chemo-
therapy or a DC treatment alone, a well-characte-
rized tumor model (MCA102 sarcoma in C57BL/6
mouse) was evaluated. Paclitaxel chemotherapy
was initiated i.p. when the tumor size was appro-
ximately 4-5 mm
2, and i.t. administration of DCs
was initiated one day after the first dose of
chemotherapy. A detailed injection schedule is
described in the Materials and Methods section.
As shown in Fig. 3, the tumors grew rapidly in
the untreated control mice. The mice treated with
paclitaxel alone and DCs alone showed a modest
suppression of tumor growth. In contrast, the
mice treated with combined systemic paclitaxel
administration plus an i.t. injection of DCs showed
a significant suppression of tumor growth. These
results strongly suggest that combined systemic
paclitaxel chemotherapy plus an i.t. injection of
DCs has greater suppressive activity on MCA102
sarcoma growth than either paclitaxel or DC treat-
ment alone in vivo. The representative images of
the actual tumor sizes in each group on day 15
Fig. 3. Significant regression of tumor growth in the com-
bined treatment group in contrast to the control groups.
Using a well-characterized tumor model (MCA102 sar-
coma in C57BL/6 mouse), a synergistic effect of a sys-
temic paclitaxel administration by i.p. together with an i.t.
injection of DCs was evaluated in comparison to chemo-
therapy or DC treatment alone. The data represent the
mean ± SD of three independent experiments.
Fig. 2. In vitro cytotoxic effect of paclitaxel on MCA102
murine fibrosarcoma cells and DCs. The cytotoxicity ef-
fects of etoposide, ifosfamide, doxorubicine, and paclitaxel
on MCA102 tumor cells (A) and the cytotoxicity effects of
paclitaxel on DCs (B) were measured by an MTT assay in
vitro. Paclitaxel was found to have the most profound
cytotoxic effect on MCA102 tumor cells.
A
BCombined Chemotherapy and Dendritic Cells for Treatment of Murine Fibrosarcoma
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and day 42 post-tumor cell injection are shown in
Fig. 4.
Apoptosis of MCA102 tumor cells in tumor tissue
after the combined treatment in vivo
To evaluate the apoptosis of MCA102 tumor
cells in tumor tissue after each treatment, the
TUNEL assay was performed with paraformal-
dehyde-fixed tissue specimens. Apoptotic cells
stained brown were easily observed in the tumor
tissues treated with the combination of paclitaxel
and DCs or paclitaxel alone but not as readily
observed in the tissues treated with DCs alone
(Fig. 5). These results indicate that an i.p. injection
of paclitaxel caused apoptosis of MCA102 tumor
cells in vivo.
Immunohistochemical staining of tumor tissue
after the combined treatment
In order to observe the migration of immune
cells to the tumor mass in vivo, an immunohisto-
chemical stain was performed using anti-CD11c.
When the border areas between the tumor tissue
and normal tissue were examined, more immune
cells, such as macrophages and neutrophils, were
detected in frozen sections from the combined
treatment group, as compared to the control
group to which only cell culture medium was in-
jected (Fig. 6).
Persistent antitumor memory after the combined
treatment
To further evaluate the memory of antitumor
immunity in vivo after the combined treatment of
paclitaxel plus DCs, a second challenge of the
same MCA102 tumor cells was delivered to the
mice, in which the tumor had completely re-
gressed. As shown in Fig. 7, in three experimental
mice, a very small tumor appeared around day
nine after the injection, but disappeared quickly.
In contrast, as observed in the previous control
experiments, tumors formed in the control mice
after a second challenge. These results suggested
that the tumor-free mice were able to resist a
repeat challenge with the same type of tumor.
DISCUSSION
The present study demonstrates that a com-
bination therapy of conventional paclitaxel che-
motherapy and an i.t. injection of DCs is effective
against fibrosarcoma in a C57BL/6 mouse model
of flank fibrosarcoma that was syngeneic to the
animal. The data showed that the combined
treatment resulted in the complete suppression of
tumor growth, whereas the single treatments of
chemotherapy or DC injection alone generated
only a partial regression of the tumor. In addition,
the combined therapy produced tumor-specific
Fig. 4. Representative photographs
of animals showing the tumor
masses 15 days and 42 days after
the tumor cell injection. The mouse
treated with the combined therapy
showed the most significant sup-
pression of tumor growth. (A, B,
C, and D) mice treated with medi-
um, paclitaxel, DC, or paclitaxel
plus DC, respectively, on day 15.
(E, F, G, and H) mice treated with
medium, paclitaxel, DC, or pacli-
taxel plus DC, respectively, on day
42.Gwang-Seong Choi, et al.
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Fig. 5. Determination of apoptosis of MCA102 tumor cells in the tumor tissues by the TUNEL assay. Apoptotic cells stained
brown were easily observed in the tumor tissues treated with the combined treatment (D) or paclitaxel treatment alone
(B) but not in tissues treated with DC treatment alone (C) or medium injection (A). Arrows indicate the apoptotic cells.
Fig. 6. Immunohistochemical staining of the tumor tissue
after the combined treatment. When the border areas
between the tumor tissue and normal tissue were observed,
more immune cells, such as macrophages and neutrophils,
were detected in the mouse specimen from the combined
treatment (B) than that from the medium control specimen
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cytotoxic T cells that were able to protect animals
from a subsequent tumor challenge with the same
type of tumor, suggesting that the animals had
acquired long-term antitumor immunity. These
results suggest that the combination therapy of
paclitaxel chemotherapy together with an i.t. injec-
tion of syngeneic DCs can be a practical method
for the treatment of fibrosarcoma.
DC therapy has been considered to be one of the
emerging strategies for the treatment of patients
with advanced cancer, especially for patients that
resist conventional therapies, such as surgery, irra-
diation, and chemotherapy. Several different stra-
tegies using DCs in immunotherapy against tumors
have been studied; these strategies are based on
DCs' ability to present MHC-restricted tumor anti-
gens. These strategies include: pulsing DCs with
defined peptides or a tumor cell lysate, genetically
modifying DCs to express tumor antigens and
fusing DCs with tumor cells.
7-11 These manipulated
DCs were then reinfused back to the recipient host.
The above methods can induce CTLs directed
specifically against the tumor, but they require an
ex vivo step to expose the DCs to the tumor. The
strategy used in the present study is similar to the
previous strategies, but it eliminated the ex vivo
step of loading the DCs with a tumor antigen.
Instead, our DCs were injected into a tumor mass
and engulfed the apoptotic bodies generated by the
paclitaxel treatment directly in vivo. Using this
method, we can eliminate the use of any surgical
procedures for obtaining tumor tissues, reduce the
dose of the chemotherapeutic agent to induce the
apoptosis of tumor cells, and enhance direct con-
tact of DCs to apoptotic tumor cells without migra-
tion from a remote area. Based on this hypothesis,
we assumed that, in this study, the DCs we in-
jected into the tumor recruited tumor antigens by
uptaking apoptotic tumor cell bodies in vivo. Then,
these DCs moved to the regional lymph node and
activated the immune system. Therefore, our fu-
ture studies should generate in vivo evidence that
proves that DCs obtain the tumor antigen and
stimulate the CTL response against the tumor after
moving to the regional lymph node. Our observa-
tions also suggest that it is not necessary to identify
specific tumor antigens for immunotherapy using
DCs, and low-dose chemotherapy may be a
sufficient method for providing antigens to DCs in
the milieu of the tumor.
Tong et al., Shin et al., and Yu et al. previously
reported an antitumor strategy similar to the
strategy shown in the present study.
12,14,15 Tong et
al. evaluated the synergistic effect of systemic
cyclophosphamide chemotherapy combined with
an i.t. injection of DCs for the treatment of colon
adenocarcinoma and melanoma. Shin et al. tested
the synergistic effect of an i.t. injection of com-
bined vincristine and DCs for the treatment of
fibrosarcoma, and Yu et al. investigated the com-
bination of paclitaxel and DCs for the treatment
of advanced stage breast cancer. We noted the
following differences between our method and
that of Shin's group. First, we used a different
chemotherapeutic agent, paclitaxel, and this drug
was injected i.p. instead of i.t. Second, the injec-
tion schedules of the antitumor drug and DCs
differed. We injected DCs one day after the
paclitaxel injection, whereas Shin's group injected
DCs eight hours after a vincristine injection. We
hypothesized that there would be more apoptotic
cellular bodies available to the DCs one day after
chemotherapy, and a systemic injection of the
chemotherapeutic drug would generate a higher
regression of the tumor. Also, we asserted that
this procedure would lower the treatment burden
to the host animals. Yu et al. utilized the same
combined treatment but in a different tumor model
Fig. 7. Persistent antitumor memory after the combined
treatment. A second challenge of the same MCA102 tumor
cells to the mice, in which tumors had completely
regressed in the previous experiments, was carried out. A
very small-sized tumor appeared around day nine after
the second injection, but it disappeared quickly thereafter.
Age-matched normal mice were also injected with the
same type of tumor for controls. The data represent the
means ± SD of triplicate experiments.Gwang-Seong Choi, et al.
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with different cycles of chemotherapy. Yu's group
used 7.5 mg/kg of paclitaxel for their animal
experiments but we injected a smaller amount, 5
mg/kg, in the present study. They also showed
that the combination of DC administration with
repeated cycles of paclitaxel and dexamethasone,
which is similar to real clinical practice, resulted in
the induction of antitumor response.
DCs are known to be the most potent antigen-
presenting cells (APCs) of the immune system.
They are capable of activating T cells in response
to both new and recall antigens.
1-3 The maturation
state of DCs is one of the factors that affects the
capacity of DC to induce antigen-specific CTLs. We
used immature DCs in our study because immature
DCs have phagocytic activity, and they can
effectively capture exogenous antigens. These
immature cells were produced by culturing DC
precursors from bone marrow in the presence of
GM-CSF and IL-4 for six days. However, there is
still a need to evaluate the degree to which DCs
matured in vitro induce the antitumor effect when
combined with low-dose chemotherapy. In addi-
tion, the effects of various routes of DC injection
need to be evaluated. Besides these, the following
issues should also be elucidated: (1) Which subset
of DCs can stimulate antitumor immunity most
effectively? (2) What is the potential for a combi-
nation therapy of a DC-based treatment with other
therapies (such as radiotherapy or cytokine
therapy)? (3) Can a steroid hormone (such as dexa-
methasone) used in conventional cancer treatment
inhibit the anticancer immunity induced by a DC-
based treatment?
In summary, a combination therapy of systemic
paclitaxel chemotherapy together with an i.t. injec-
tion of DCs is a promising method for the eradica-
tion of fibrosarcoma in vivo. The data presented in
this study and in previous studies strongly suggest
that the presented strategy may overcome the drug
resistance problems associated with conventional
chemotherapy, and this strategy could be applied to
a wide variety of tumors in clinical settings.
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